Biocardia Receives U.S. Patent Covering Morph Product Family Design
October 04, 2017
SAN CARLOS, Calif. –BioCardia®, Inc. [OTC: BCDA]), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, with clinical programs in heart failure, today announced the issuance of United States Patent No. 9,775,963 entitled, “Steerable Endoluminal Devices and Methods.”
BioCardia CEO Peter Altman, PhD stated, “This new patent provides greater protection for our Morph vascular navigation products, which have broad clinical application to enable complex interventional procedures. Moving forward, we will continue to pursue our patent strategy of protecting active programs where we are investing our resources.”
The Morph steerable, thin-walled catheter shaft technology is designed to navigate through tortuous anatomy, customize the shape of the catheter to the patient's anatomy and their clinical needs during a procedure, and offer significant back-up support once positioned. To date, Morph products have been used in more than 10,000 clinical procedures worldwide.
BioCardia, Inc., headquartered in San Carlos, CA, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP® and CardiALLO® cell therapies are the Company’s biotherapeutic product candidates in clinical development. The Company's current products include the Helix™ transendocardial delivery system and the Morph® steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.
Forward Looking Statements
This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardia’s business and product development plans and overall market conditions. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.
We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation. As a result of these factors, we cannot assure you that the forward-looking statements in this presentation will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 30, 2017, including under the caption titled “Risk Factors.” BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
David McClung, Vice President Finance & CFO
Michelle McAdam, Chronic Communications, Inc.
Henry Ford Health System
Cell & Gene
The Big Biz show
CALL US NOW
EMAIL US NOW